Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E
about
Downregulation of the tumor-suppressor miR-16 via progestin-mediated oncogenic signaling contributes to breast cancer developmentNovel Molecular Markers for Breast CancerCyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patientsToo much cleavage of cyclin E promotes breast tumorigenesis.CDK2-AP1 inhibits growth of breast cancer cells by regulating cell cycle and increasing docetaxel sensitivity in vivo and in vitroThe serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase.Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERα-positive breast cancer cellsFunctional characterization of the 19q12 amplicon in grade III breast cancersCyclin-dependent kinase 2 protects podocytes from apoptosisPKCiota promotes ovarian tumor progression through deregulation of cyclin E.Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast CancerHbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells.Cell cycle proteins as promising targets in cancer therapyCyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer.A CDK2 activity signature predicts outcome in CDK2-low cancers.Information theoretic sub-network mining characterizes breast cancer subtypes in terms of cancer core mechanisms.Mobility-based prediction of hydration structures of protein surfaces.Testosterone regulation of cyclin E kinase: A key factor in determining gender differences in hepatocarcinogenesis.Cell Cycle Regulation in Treatment of Breast Cancer.Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer.Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer.
P2860
Q22000752-AB05C0A4-27A6-491E-BBA8-7F24CDE80D8AQ26753160-7138CFDE-567E-487C-AC6B-FB35F1B5C456Q33570330-260A6861-6941-4DA3-8E00-12E875E413AFQ34220979-A06206A6-618B-4E27-8213-69745F72A1E8Q34221065-485C519A-31D8-4F8E-8498-26E8B98B1912Q34787090-D5EB5BF7-C207-45AA-A318-C2929BC65477Q35185357-5AAA2402-399F-41E6-9658-72F91D6133C0Q36187728-78839A2B-24E7-4A1A-B0E1-50005093BF98Q36245567-7D7AF4BE-24FF-4734-BD57-18DE833B04DBQ36579695-414F3D50-C12C-481C-8A99-954975B8CC60Q36869444-33811001-C2CF-4335-AA09-9FAA0A679201Q37057171-D6786FB7-702A-41F4-986A-35AB96FAA74BQ37172133-EF520A56-7499-470D-8A61-F8361AE4532EQ37693690-AF804038-89F4-4455-88CD-4292D3202EDDQ37716464-B2FD0832-C773-4D67-9E78-9AB3518C4597Q39209798-F5E2D5E8-3C38-45C9-9465-0612912E75AAQ39315724-716E9248-2CA0-4E05-9C5E-1A3E6114F318Q47676752-1255DF0F-0984-4F27-B4B0-F4B1ECFB093EQ48103177-015462F6-56F9-44F8-A977-0A351C383CB2Q49544319-7FFF8839-DD1E-43E8-A274-49D0C4C584F6Q49558301-0D758825-01DA-444E-BA87-1F280FE799F2Q52955581-E95BB241-3CB1-4D76-985D-D9E607459E8D
P2860
Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@ast
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@en
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@nl
type
label
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@ast
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@en
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@nl
prefLabel
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@ast
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@en
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@nl
P2093
P2860
P1433
P1476
Cdk2 is required for breast ca ...... lar-weight isoform of cyclin E
@en
P2093
Carolyn S Van Pelt
Laurent Meijer
P2860
P304
P356
10.1158/0008-5472.CAN-10-4086
P407
P577
2011-03-08T00:00:00Z